Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.94
CBRX's Cash to Debt is ranked higher than
71% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. CBRX: 2.94 )
CBRX' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 2.94

Equity to Asset 0.75
CBRX's Equity to Asset is ranked higher than
82% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. CBRX: 0.75 )
CBRX' s 10-Year Equity to Asset Range
Min: -1.39   Max: 0.88
Current: 0.75

-1.39
0.88
F-Score: 4
Z-Score: -2.23
M-Score: 27.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 20.10
CBRX's Operating margin (%) is ranked higher than
90% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. CBRX: 20.10 )
CBRX' s 10-Year Operating margin (%) Range
Min: -835.82   Max: 53.25
Current: 20.1

-835.82
53.25
Net-margin (%) 22.94
CBRX's Net-margin (%) is ranked higher than
95% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. CBRX: 22.94 )
CBRX' s 10-Year Net-margin (%) Range
Min: -857.47   Max: 47.67
Current: 22.94

-857.47
47.67
ROE (%) 14.30
CBRX's ROE (%) is ranked higher than
89% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. CBRX: 14.30 )
CBRX' s 10-Year ROE (%) Range
Min: -709.28   Max: 99.5
Current: 14.3

-709.28
99.5
ROA (%) 11.16
CBRX's ROA (%) is ranked higher than
94% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. CBRX: 11.16 )
CBRX' s 10-Year ROA (%) Range
Min: -185.12   Max: 56.89
Current: 11.16

-185.12
56.89
ROC (Joel Greenblatt) (%) 31.43
CBRX's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. CBRX: 31.43 )
CBRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1904.92   Max: 596.64
Current: 31.43

-1904.92
596.64
Revenue Growth (%) -19.50
CBRX's Revenue Growth (%) is ranked higher than
50% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. CBRX: -19.50 )
CBRX' s 10-Year Revenue Growth (%) Range
Min: -44.8   Max: 95.1
Current: -19.5

-44.8
95.1
» CBRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CBRX Guru Trades in Q3 2013

Jim Simons 184,950 sh (+1115.74%)
» More
Q4 2013

CBRX Guru Trades in Q4 2013

Jim Simons 164,250 sh (-11.19%)
» More
Q1 2014

CBRX Guru Trades in Q1 2014

Jim Simons 124,050 sh (-24.47%)
» More
Q2 2014

CBRX Guru Trades in Q2 2014

Jim Simons 94,750 sh (-23.62%)
» More
» Details

Insider Trades

Latest Guru Trades with CBRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2011-12-31 Sold Out 0.0036%$15.28 - $21.6 $ 6.02-68%0
Joel Greenblatt 2011-09-30 New Buy$15.68 - $27.12 $ 6.02-70%11210
Richard Perry 2011-06-30 Sold Out 0.21%$23.92 - $32.24 $ 6.02-78%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.40
CBRX's P/E(ttm) is ranked higher than
81% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. CBRX: 27.40 )
CBRX' s 10-Year P/E(ttm) Range
Min: 4.79   Max: 296.3
Current: 27.4

4.79
296.3
P/B 1.60
CBRX's P/B is ranked higher than
84% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. CBRX: 1.60 )
CBRX' s 10-Year P/B Range
Min: 1.51   Max: 63.23
Current: 1.6

1.51
63.23
P/S 2.40
CBRX's P/S is ranked higher than
74% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. CBRX: 2.40 )
CBRX' s 10-Year P/S Range
Min: 1.44   Max: 30.06
Current: 2.4

1.44
30.06
PFCF 20.80
CBRX's PFCF is ranked higher than
90% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CBRX: 20.80 )
CBRX' s 10-Year PFCF Range
Min: 3.7   Max: 95.11
Current: 20.8

3.7
95.11
EV-to-EBIT 23.42
CBRX's EV-to-EBIT is ranked higher than
80% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. CBRX: 23.42 )
CBRX' s 10-Year EV-to-EBIT Range
Min: 1.8   Max: 202.5
Current: 23.42

1.8
202.5
Current Ratio 3.52
CBRX's Current Ratio is ranked higher than
79% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. CBRX: 3.52 )
CBRX' s 10-Year Current Ratio Range
Min: 0.4   Max: 12.62
Current: 3.52

0.4
12.62
Quick Ratio 3.00
CBRX's Quick Ratio is ranked higher than
80% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. CBRX: 3.00 )
CBRX' s 10-Year Quick Ratio Range
Min: 0.25   Max: 11.83
Current: 3

0.25
11.83

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 11.15
CBRX's Price/Net Current Asset Value is ranked higher than
90% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CBRX: 11.15 )
CBRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.81   Max: 1841.73
Current: 11.15

1.81
1841.73
Price/Tangible Book 2.50
CBRX's Price/Tangible Book is ranked higher than
82% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. CBRX: 2.50 )
CBRX' s 10-Year Price/Tangible Book Range
Min: 1.58   Max: 264.86
Current: 2.5

1.58
264.86
Price/DCF (Projected) 6.62
CBRX's Price/DCF (Projected) is ranked higher than
76% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. CBRX: 6.62 )
CBRX' s 10-Year Price/DCF (Projected) Range
Min: 1.42   Max: 33.05
Current: 6.62

1.42
33.05
Price/Median PS Value 0.62
CBRX's Price/Median PS Value is ranked higher than
95% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. CBRX: 0.62 )
CBRX' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 27.89
Current: 0.62

0.47
27.89
Price/Graham Number 1.45
CBRX's Price/Graham Number is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.75 vs. CBRX: 1.45 )
CBRX' s 10-Year Price/Graham Number Range
Min: 0.5   Max: 53.44
Current: 1.45

0.5
53.44
Earnings Yield (Greenblatt) 4.30
CBRX's Earnings Yield (Greenblatt) is ranked higher than
70% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. CBRX: 4.30 )
CBRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 54.1
Current: 4.3

0.5
54.1
Forward Rate of Return (Yacktman) -5.32
CBRX's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. CBRX: -5.32 )
CBRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -23.2   Max: 4.1
Current: -5.32

-23.2
4.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CLB1.Germany
Columbia Laboratories, Inc., is in the business of developing, manufacturing and selling pharmaceutical products that utilize its proprietary bioadhesive drug delivery technologies to treat various medical conditions. It is focused in developing drugs that improve treatment options for women's health, an area where it have a rich heritage and proven capabilities. It has developed and brought to market five bioadhesive vaginal gel products that provide patient-friendly solutions for infertility, pregnancy support, amenorrhea, and other gynecologic conditions. The Company's Progesterone Products include Crinone and Prochieve. Crinone is a sustained release gel that delivers natural progesterone vaginally. Crinone utilizes the company's patented BDS, which enables the progesterone to achieve a preferential uptake of drug from the vagina to the uterus, or a "First Uterine Pass Effect." The product is available in both 4% and 8% concentrations, and in the U.S. is also known under the trade name Prochieve. Women's Health Market include STRIANT which utilizes the BDS to achieve controlled and sustained delivery of testosterone via the buccal cavity - the small depression in the mouth where the gum meets the upper lip above the incisor teeth. STRIANT is absorbed into the bloodstream and delivers testosterone directly into the superior vena cava (major blood vessel), bypassing the gastrointestinal system and liver. All of the products it has developed utilize its Bioadhesive Delivery System ("BDS"), which consists mainly of a polymer (polycarbophil) and an active ingredient. The BDS is based upon the principle of bioadhesion, a process by which the polymer adheres to epithelial surfaces or mucosa. Its vaginal products adhere to the vaginal epithelium; the buccal products adhere to the mucosal membrane of the gum and cheek. The polymer remains attached to epithelial surfaces or mucosa and is discharged upon normal cell turnover, a physiological process that, depending upon the area of the body, occurs every 12 to 72 hours, or longer. Both vaginal and buccal BDS products provide sustained and controlled delivery of active drug ingredients. Its extended period of attachment permits use of BDS in products when extended duration of effectiveness is desirable or required. It is substantially dependent on three third-party manufacturers for the products that it sells to marketing partners in the U.S. and around the world. It's Crinone and Prochieve vaginal gel products are manufactured in bulk by Fleet Laboratories Limited, Watford, Herts, United Kingdom ("Fleet") and filled into overwrapped single-use disposable applicators by Maropack AG, Zell, Switzerland ("Maropack"). Its customers include trade customers, such as drug wholesalers, specialty pharmacies, and chain drug stores, and its marketing partners. The Company and its marketing partners compete against established pharmaceutical and consumer product companies which market products addre
» More Articles for CBRX

Headlines

Articles On GuruFocus.com
Top Gainers of More Than 30% Within One Day Jan 19 2012 
Columbia Laboratories Inc. Reports Operating Results (10-K) Mar 10 2011 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Dec 29 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Dec 28 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Dec 28 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q) Nov 04 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q) Aug 05 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Jul 30 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q) May 06 2010 
Columbia Laboratories Inc. Reports Operating Results (10-K/A) Apr 30 2010 

More From Other Websites
Columbia Laboratories to participate in the Rodman & Renshaw 16th Annual Global Investment... Aug 27 2014
COLUMBIA LABORATORIES INC Financials Aug 08 2014
COLUMBIA LABORATORIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 06 2014
Columbia Laboratories Announces Sale Of IP And Technology For Legatrin P.M. To Lil' Drug Store... Aug 06 2014
COLUMBIA LABORATORIES INC Files SEC form 10-Q, Quarterly Report Aug 01 2014
COLUMBIA LABORATORIES INC Files SEC form 8-K, Financial Statements and Exhibits Jul 31 2014
Q2 2014 Columbia Laboratories Earnings Release - Before Market Open Jul 31 2014
Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis Jul 31 2014
Columbia Laboratories Reports Second Quarter 2014 Financial Results Jul 31 2014
Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call Jul 23 2014
Columbia Laboratories awarded U.S. patent for hydration tablets Jul 17 2014
Columbia Laboratories Expands its Intellectual Property Portfolio Following Receipt of U.S. Patent Jul 17 2014
Columbia Laboratories Added to the Russell Microcap Index Jun 26 2014
COLUMBIA LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 08 2014
COLUMBIA LABORATORIES INC Files SEC form 10-Q, Quarterly Report May 02 2014
COLUMBIA LABORATORIES INC Files SEC form 8-K, Financial Statements and Exhibits Apr 29 2014
U.S./Canada daily earnings hits & misses April 29 - 1500 ET Apr 29 2014
Columbia Laboratories' CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 29 2014
Columbia Laboratories Reports First Quarter 2014 Financial Results Apr 29 2014
Columbia Laboratories to Discuss First Quarter 2014 Financial Results on April 29th Conference Call Apr 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK